Article
Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers.
Current oncology (Toronto, Ont.) - 30 Sept 2022
O'Sullivan Dylan E, Jarada Tamer N, Yusuf Amman, Hu Leo Xun Yang, Gogna Priyanka, Brenner Darren R, Abbie Erica, Rose Jennifer B, Eaton Kiefer, Elia-Pacitti Julia, Ewara Emmanuel M, Pabani Aliyah, Cheung Winson Y, Boyne Devon J
Abstract excerpt
Real-world evidence surrounding EGFR positive NSCLC patients in Canada is limited. Administrative databases in Alberta, Canada were used to evaluate EGFR testing and mutation prevalence in de novo metastatic NSCLC, as well as the characteristics, treatment patterns, and outcomes of individuals with Exon 19, L858R and Exon20ins mutations. Between 2013-2019, 2974 individuals underwent EGFR testing, of which 451...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.